Immune Pharma To Unlock Value And Create Two Separate Pure Play Companies; Cytovia, Immune
July 11, 2017 at 16:13 PM EDT
Immune expects that the focus of Cytovia will be the European market for the drug, which has an addressable market of $175 million, while Pint will focus on the Latin America market with an addressable market of $100 million.
